Can a 59‑year‑old patient on Brilinta (ticagrelor) safely continue nabumetone 750 mg three times daily, and what alternative analgesics or protective measures are recommended?

Discontinue Nabumetone Immediately and Use Alternative Analgesics

A 59-year-old patient on Brilinta (ticagrelor) should NOT continue nabumetone 750 mg three times daily due to significantly increased bleeding risk. NSAIDs combined with dual antiplatelet therapy create an unacceptable hemorrhagic hazard that outweighs any musculoskeletal pain relief benefit.

Why NSAIDs Are Contraindicated with Ticagrelor

The 2014 AHA/ACC NSTE-ACS guidelines explicitly address this scenario 1. NSAIDs with increasing degrees of COX-2 selectivity should not be administered to patients on dual antiplatelet therapy (Class III: Harm recommendation). Even nonselective NSAIDs like nabumetone carry substantial risk when combined with ticagrelor plus aspirin 2.

The mechanism is straightforward: ticagrelor inhibits platelet aggregation via P2Y12 receptor blockade, aspirin irreversibly inhibits COX-1, and NSAIDs further impair hemostasis through COX inhibition and direct effects on platelet function 3. This triple assault on hemostasis dramatically elevates bleeding risk, particularly gastrointestinal and intracranial hemorrhage 2, 4.

The 2022 European Society of Cardiology polypharmacy review reinforces this, noting that antiplatelets combined with NSAIDs should be avoided, and patients at increased GI bleeding risk (which includes anyone on dual antiplatelet therapy) require gastroprotection if NSAIDs are absolutely necessary 2.

Recommended Stepped-Care Analgesic Approach

The 2014 AHA/ACC guidelines provide a clear algorithm for managing chronic musculoskeletal pain in patients on antiplatelet therapy 1:

First-line options (use before considering any NSAID):

• Acetaminophen up to 3000 mg daily (divided doses)
• Nonacetylated salicylates (salsalate, choline magnesium trisalicylate) - these lack antiplatelet effects
• Tramadol 50-100 mg every 4-6 hours as needed (maximum 400 mg/day in patients >75 years)
• Low-dose opioids (e.g., hydrocodone 5 mg or oxycodone 5 mg every 6-8 hours) for breakthrough pain

Second-line consideration (only if first-line inadequate): If pain remains intolerable despite the above, naproxen is the preferred NSAID if one must be used, as it has the most favorable cardiovascular profile among nonselective NSAIDs 1. However, this requires:

• Proton pump inhibitor (PPI) co-prescription (omeprazole 20-40 mg daily or equivalent) 1
• Lowest effective dose for shortest duration
• Close monitoring for bleeding signs
• Strong consideration of whether pain truly justifies the bleeding risk

Avoid entirely:

• COX-2 selective inhibitors (celecoxib, meloxicam) - explicitly contraindicated 1
• High-dose or prolonged NSAID courses
• Nabumetone at 2250 mg/day (current regimen) - this exceeds reasonable risk-benefit

Critical Ticagrelor-Specific Considerations

Your patient's ticagrelor regimen matters. The FDA label specifies that ticagrelor should be used with aspirin 75-100 mg daily only 5. Higher aspirin doses (>100 mg) reduce ticagrelor's effectiveness 4.

The 2017 AHA/ACC performance measures explicitly warn that NSAIDs increase major adverse events in MI patients through impaired infarct healing, increased rupture risk, acute kidney injury, and compounded bleeding risk 4.

Practical Implementation

Immediate actions:

1. Stop nabumetone today
2. Start acetaminophen 1000 mg three times daily (with meals)
3. Prescribe omeprazole 40 mg daily (if not already on PPI for gastroprotection with ticagrelor) 1
4. Add tramadol 50 mg every 6 hours as needed for breakthrough pain
5. Verify aspirin dose is 75-100 mg daily (not higher) 6, 5

If pain remains inadequate after 1-2 weeks:

• Consider physical therapy, topical agents (lidocaine patches, capsaicin), or intra-articular injections
• Evaluate whether pain source requires orthopedic consultation
• Only if truly refractory: naproxen 250-375 mg twice daily with PPI, accepting increased bleeding risk

Common Pitfalls to Avoid

• Do not assume nabumetone is "safer" because it's a prodrug - its active metabolite (6-MNA) still inhibits COX and affects platelet function 3
• Do not continue NSAIDs "just until the next appointment" - bleeding events can occur within days
• Do not forget PPI prophylaxis if any NSAID is ultimately deemed necessary - this is Class I recommendation 1
• Do not use COX-2 inhibitors thinking they're safer for cardiovascular patients - they're explicitly contraindicated 1

The evidence consistently demonstrates that combining NSAIDs with ticagrelor-based dual antiplatelet therapy substantially increases bleeding complications without proportionate analgesic benefit that cannot be achieved through safer alternatives 2, 1, 4.